CD8A and melanoma: Therefore, these nanoparticles blocked the immunosuppressive PD-L1 receptors placed on the tumoral cell while turned on the 4-1BB receptors placed on CD8+ surface which triggered a potent antitumoral activity against murine melanoma and colon cancer models (Figure 5).